The Michael J. Fox Foundation for Parkinson's Research (MJFF) is the largest nonprofit funder of Parkinson's research in the world, and, unusually for this series, it files a full public tax return. It is donor-funded, evergreen, and structured as a grantmaker rather than an investor.

Vera Therapeutics spent six years turning a drug that had failed in lupus, MS, and arthritis into an approved kidney medicine. On 7 July 2026 the FDA cleared atacicept, and in the same moment flipped a dormant royalty owed to Merck KGaA into a live, cash-paying obligation. Vera is

A royalty monetisation is characterised separately by tax law, accounting, bankruptcy law, and its commercial terms. The four answers can differ on the same deal. Only the tax answer decides whether the upfront cash is income this year or deferred across the life of the stream. This piece covers how

The development funding bond is a royalty deal that was never a royalty: fixed multiple, fixed schedule, guaranteed by the parent, paid regardless of sales. Why both sides chose debt over a true sale, the tax and accounting logic, and why the structure stays a category of two.

A decade in, no token has paid a pharmaceutical royalty. When decentralized science finally produced a commercial deal, the money went to equity holders, which is exactly where securities law sends it. Every eighteen months someone announces that pharmaceutical royalties are about to go on-chain. The pitch is stable:

The week in numbers July 4 to July 11, 2026: four acquisitions, six royalty-bearing originations, one synthetic royalty (Oberland / MeiraGTx), one €3.0B structured-equity monetisation (Apollo / Bayer), one structured-credit refinancing (OrbiMed / TOI), one milestone cash event (Aligos), and two negative royalty re-rates (Ionis WAINUA, GSK / Alector)

Since the September 2025 analysis, the disease-linked bond category has separated into families that no longer behave alike. Instruments that place principal at risk on a parametric trigger or a measured outcome saw little or no new issuance in 2024 to 2026. Instruments that rest on a sovereign credit,

Venture philanthropy: the RD Fund is donor-backed and evergreen, with $59.5M net assets, 18 companies and $0 royalty income on file. Its value is upstream, originating the rare-disease assets whose royalties later land on other desks.

Pacira BioSciences owns its non-opioid drugs rather than licensing a platform, so its royalty life runs backwards: it litigated one royalty out of existence, wrote a negative royalty against EXPAREL's own volumes to 2039, and in June 2026 sold iovera° to Zimmer Biomet for up to $140 million.